Bioadhesive Oral Mucosal Drug Formulations for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral dosage forms often result in low absorption efficiency and lengthy onset times due to metabolism in the gastrointestinal tract, and few are designed for effective oral transmucosal delivery, which can lead to erratic absorption and reduced bioavailability, especially for lipophilic drugs.
Innovation Solution
Development of bioadhesive drug formulations that adhere to the oral mucosa, allowing for sustained drug delivery and controlled dissolution kinetics, independent of pH, and are designed as various forms such as lozenges, tablets, or films to enhance absorption through the oral mucosa, reducing gastrointestinal uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral dosage forms are designed for GI delivery, then they are non-invasive and easily administered, but absorption efficiency is low and onset time is lengthy due to GI metabolism and first-pass metabolism
Solution Approach 1:
The invention uses the oral mucosa as an intermediary absorption route between the oral cavity and systemic circulation, bypassing the GI tract. The dosage form is designed to deliver drug through the highly vascularized oral mucosal tissue directly into the bloodstream, avoiding first-pass metabolism while maintaining ease of oral administration.
2Ease of operation
If oral dosage forms are designed for GI delivery, then they are easily administered, but onset time is lengthy and absorption characteristics are erratic
Solution Approach 1:
The oral mucosa serves as a direct pathway to systemic circulation, eliminating the time-consuming GI transit and absorption process. The highly vascularized mucosal tissue enables rapid drug entry into the bloodstream, achieving fast onset while maintaining simple oral dosing.
3Productivity
If oral transmucosal delivery is used, then onset time is short and bioavailability is improved, but there is enhanced potential for swallowing the medication due to saliva generation and backward flow
Solution Approach 1:
The dosage form incorporates bioadhesive materials that pre-establish strong attachment to the oral mucosa before saliva flow can cause swallowing. This preliminary adhesion action prevents the dosage form from being displaced by saliva generation and backward flow, ensuring reliable transmucosal delivery.
Solution Approach 2:
The bioadhesive material acts as an intermediary between the dosage form and oral mucosa, creating a stable bond that resists saliva-induced displacement. This adhesive intermediary ensures the dosage form remains in place for efficient drug absorption despite the dynamic oral environment.
4Quantity of substance
If larger dosage forms are used for oral transmucosal delivery, then drug loading is increased, but saliva response is increased leading to increased swallowing and removal from oral mucosa
Solution Approach 1:
The bioadhesive material establishes strong preliminary attachment to the oral mucosa, anchoring the dosage form in place. This pre-established adhesion prevents saliva flow from displacing or removing the dosage form, even when larger sizes are used to increase drug loading capacity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioadhesive formulations provide rapid and consistent drug absorption, improved bioavailability, and prolonged therapeutic effects by minimizing swallowing and enhancing drug adherence to the mucosa, leading to more predictable pharmacokinetic profiles and reduced side effects.
Implementation Method 1
the formulations have bioadhesive properties which facilitate adherence to the oral mucosa during administration
Implementation Method 2
the drug is absorbed through the epithelial membranes of the oral cavity
Data Source
AI summary
Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.